Today, we are renewing our organization by bringing in new senior talent and increasing accountability at every level of the company. We are ensuring that we have the right people with the right skills in place to build a strong foundation for growth.

Today, we are strengthening our global manufacturing and quality operations and bringing them up to world-class standards, we are implementing a plan to reduce risk, increase capacity and renew the organization. These important changes will allow us to continue to provide patients around the globe with access to our breakthrough treatments.

Today, we have the leadership we need to carry Genzyme into the future. Our new President of Manufacturing Operations developed a manufacturing set of solutions for Eli Lilly, when it faced challenges like our own, and lead that company to become a model for the FDA when they instruct their inspectors.

Today, we're enhancing our quality processes. Our Senior Vice President of Global Product Quality put together a comprehensive global quality system for Gilead Sciences, and remediated both a warning letter and a consent decree at Genentech and at Aventis Behring. He learned the principles guiding his quality management philosophies at Johnson and Johnson.

Today, with our manufacturing and supply recovery on track, we expect revenue to increase at a compound annual growth rate of 12 percent between 2008-2013. We're working closely with regulatory authorities globally to achieve the FDA mandated goals.

Today, we are hiring for up to 500 new jobs in manufacturing and quality. These hires align with one of our key areas of focus: improving and expanding manufacturing. It's critical to patients and Genzyme's future that we are appropriately resourced to meet and exceed the goals we've set for global manufacturing excellence.